# Psilocybin Microdosing on Cognition, Mood and Quality of Life

> **NCT07449351** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Yale University** · enrollment: 20 (estimated)

## Conditions studied

- Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI

## Interventions

- **DRUG:** Psliocybin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07449351
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07449351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07449351, "Psilocybin Microdosing on Cognition, Mood and Quality of Life". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07449351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*